Phase 3 Trial of SRG-514 in Triple Negative Breast Cancer Undergoing Surgery
A Phase 3 trial is underway to evaluate SRG-514, an intraoperative treatment for patients with triple negative breast cancer.
Asset / Drug
Drug and asset intelligence for SRG-514 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.